AT-7687 / Antag Therap - LARVOL DELTA

Antag Therapeutics initiates Phase 1a trial of AT-7687, a first-in-class GIPR antagonist designed to address key gaps in obesity treatment (GlobeNewswire) - "Antag Therapeutics...today announces the initiation of its first-in-human Phase 1 clinical trial evaluating AT-7687, a first-in-class Glucose-Dependent Insulinotropic Polypeptide Receptor (GIPR) antagonist....The Phase 1a trial is a double-blind, randomized, placebo-controlled study designed to evaluate the safety, tolerability, and pharmacokinetics of AT-7687. It will be conducted in healthy lean and healthy subjects living with obesity, with topline results expected in Q4 2025....Following this study, the Company plans to investigate AT-7687 as a combination therapy in patients treated with a GLP-1 receptor agonist, with the study expected to commence at the end of 2025."

Trial status • Obesity

GIP receptor antagonism eliminates paradoxical growth hormone secretion in some patients with acromegaly. (PubMed, J Clin Endocrinol Metab) - "Of 25 patients with acromegaly, seven had paradoxical GH secretion during OGTT, and pharmaceutical GIPR blockade abolished this secretion in four. Corresponding somatotroph adenomas abundantly expressed GIPR, suggesting a therapeutic target in this subpopulation of patients. In vitro and ex vivo analyses confirmed the role of GIP and the effects of the antagonist."

Journal • Acromegaly • Endocrine Disorders • Pituitary Gland Carcinoma